Market Snapshot

Market Synopsis:

Global Creatinine Test market is valued at USD 995.1 Million in 2021 and is projected to attain a value of USD 2,356.7 Million by 2028 at a CAGR of 16.1% during the forecast period, 2022–2028. Over the forecast period, the global Creatinine Test market is expected to increase significantly. Muscle metabolism produces creatinine as an endogenous by-product. This waste product is measured in the clinical laboratory to determine the glomerular filtration rate (GFR), which further describes the renal function of patients. Jaffe's kinetic methods and enzymatic methods are used in the majority of modern creatinine assays.

Increased creatinine levels in the urine, together with an abrupt decline in urine output, are usually indicators of AKI or ARF. As a result, the rise in and high rate of hypoalbuminemia caused by COVID-19 (coupled with the growing elderly population and other variables) is predicted to increase the number of instances of AKI/ARF, thereby supporting market growth in the first half of the forecasted period.

Rising Prevalence of Kidney Disorders

Kidney disease is a leading cause of death all over the world. Multiple renal therapies necessitate constant monitoring of components like creatinine and albumin, as well as their ratios, which necessitates the use of multiple urine analysis products and procedures. Urine analysis is commonly used in the diagnosis and treatment of renal disorders. Clinicians can use biochemical urine analysis to determine the levels of chemical substances in the urine (such as creatinine, urobilinogen, bilirubin, ketones, and glucose). Chronic kidney illness, acute kidney injury, and acute renal failure are all indicated by abnormal levels of these chemicals in the urine. As a result, the rising prevalence of renal illnesses will be the primary growth driver for this market, ensuring that demand for albumin and creatinine tests remains stable.

High Cost of Automated Analyzers

Most small hospitals and clinics still favour semi-automated technology or manual analysis due to smaller workloads. Large hospitals with heavy workloads are more likely to adopt automated instruments, therefore the revenue generated can justify the expenditures of implementing automated analyzers. This makes it difficult for automated analyzers to break into the market, particularly in emerging economies, posing a significant barrier to industry expansion.

The Creatinine Test market scope can be tabulated as below:

Market Segmentation:

The Global Creatinine Test Market can be segmented by Test Type into Blood Test, Urine Test and Others. By Product into Consumables and Instruments. By Application into Urinary Tract Obstruction, Renal Failure, Kidney Cancer, Glomerulonephritis and Others. By End-Use into Hospital and Clinics, Diagnostic Centre and Research Institutes. Based on Region, the Creatinine Test Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

North America to Continue Dominating the Creatinine Test Market

Owing to the high prevalence of the condition and the rise in government programmes to aid early diagnosis, North America held the biggest market share in 2019.The increased prevalence of various kidney illnesses, well-developed technology, high healthcare expenditures, and the existence of prominent players are all factors contributing to this. The European market for creatinine is the second-largest. Increasing government backing, rising healthcare expenditures, and well-developed technology are the market's key driving forces.

Key Players:

Key participants operating in the Creatinine Test market are: BioAssay Systems, Abcam plc, Arbor Assays, Thermo Fisher Scientific, Randox Laboratories Ltd., Sentinel CH. SpA, DiaSys Diagnostic Systems GmbH, MedTest Holdings, Inc. (Pointe Scientific, Inc.), Abbexa Ltd., and General Atomics, Inc. (Diazyme Laboratories, Inc.).

The Creatinine Test market is segmented as follows:

• Test Type
  • Blood Test
  • Urine Test
  • Others